| DrugRepV_0010 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Zika virus | GZ01, a recent Asian lineage | NA | Plaque assay | No significant effect (45 %) | Approved | 29033372 |
| DrugRepV_0066 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Zika virus | MR766 | NA | Plaque assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_0067 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Plaque assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_0068 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_0069 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_0070 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | Zaire | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_0071 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Chikungunya virus | 181/25 | NA | Plaque assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_0072 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | 181/25 | NA | Plaque assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_0078 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Zika virus | Puerto Rico strain PRVABC-59 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 28185815 |
| DrugRepV_0079 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Zika virus | Puerto Rico strain PRVABC-59 | NA | Real-time PCR | Decrease (4 Log viral titer (copies/ml)) | Approved | 28185815 |
| DrugRepV_0080 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Zika virus | Puerto Rico strain PRVABC-59 | NA | Plaque assay | Decrease (>99 %) | Approved | 28185815 |
| DrugRepV_0081 | Avonex | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 28185815 |
| DrugRepV_0082 | Avonex | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Real-time PCR | Decrease (5 Log viral titer (copies/ml)) | Approved | 28185815 |
| DrugRepV_0083 | Avonex | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Plaque assay | Decrease (>99 %) | Approved | 28185815 |
| DrugRepV_0084 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 28185815 |
| DrugRepV_0085 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Real-time PCR | Decrease (>4 Log viral titer (copies/ml)) | Approved | 28185815 |
| DrugRepV_0086 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Plaque assay | Decrease (>99 %) | Approved | 28185815 |
| DrugRepV_0087 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 28185815 |
| DrugRepV_0088 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Real-time PCR | Decrease (5 Log viral titer (copies/ml)) | Approved | 28185815 |
| DrugRepV_0089 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | Puerto Rico strain PRVABC-59 | NA | Plaque assay | Decrease (>90 %) | Approved | 28185815 |
| DrugRepV_0093 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0105 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0106 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0107 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0108 | Cabazitaxel | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Approved | 28099856 |
| DrugRepV_0114 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0115 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0121 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Approved | 28099856 |
| DrugRepV_0138 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (80 %) | Approved | 28099856 |
| DrugRepV_0139 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (90 %) | Approved | 28099856 |
| DrugRepV_0140 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0150 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_0151 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Approved | 28099856 |
| DrugRepV_0152 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Approved | 28099856 |
| DrugRepV_0159 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0160 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (90 %) | Approved | 28099856 |
| DrugRepV_0161 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0171 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 28099856 |
| DrugRepV_0172 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_0173 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (40 %) | Approved | 28099856 |
| DrugRepV_0181 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Real-time PCR | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_0182 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | Real-time PCR | No significant effect (20 %) | Approved | 28099856 |
| DrugRepV_0186 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | TCID50 assay | Decrease (80 %) | Approved | 28099856 |
| DrugRepV_0187 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | TCID50 assay | Decrease (75 %) | Approved | 28099856 |
| DrugRepV_0188 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | Mex2-81 | NA | TCID50 assay | Decrease (95 %) | Approved | 28099856 |
| DrugRepV_0189 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | TCID50 assay | No significant effect (30 %) | Approved | 28099856 |
| DrugRepV_0190 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | TCID50 assay | Decrease (75 %) | Approved | 28099856 |
| DrugRepV_0191 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | Mex2-81 | NA | TCID50 assay | No significant effect (0 %) | Approved | 28099856 |
| DrugRepV_0198 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | VLP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0208 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOLA/Mayinga-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved, Investigational | 27890675 |
| DrugRepV_0237 | Gleevec | Antineoplastic and Immunomodulating Agents | Leukemia | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (3.60 ± 0.63 Ct) | Approved | 27801778 |
| DrugRepV_0238 | Gleevec | Antineoplastic and Immunomodulating Agents | Leukemia | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (3.49 ± 0.54 Ct) | Approved | 27801778 |
| DrugRepV_0245 | Tasigna | Antineoplastic and Immunomodulating Agents | Myeloid leukemia | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (3.59 ± 0.57 Ct) | Approved, Investigational | 27801778 |
| DrugRepV_0246 | Tasigna | Antineoplastic and Immunomodulating Agents | Myeloid leukemia | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Increase (?0.13 ± 0.33 Ct) | Approved, Investigational | 27801778 |
| DrugRepV_0256 | Gleevec | Antineoplastic and Immunomodulating Agents | Leukemia | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (1.55 ± 0.20 Ct) | Approved | 27801778 |
| DrugRepV_0262 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | TCID50 assay | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0263 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | TCID50 assay | Decrease (~20 Fold) | Approved | 27466418 |
| DrugRepV_0264 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | TCID50 assay | Decrease (>10 Fold) | Approved | 27466418 |
| DrugRepV_0265 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | TCID50 assay | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0266 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | Real-time PCR | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0267 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | Real-time PCR | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0268 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Real-time PCR | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0269 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Real-time PCR | Decrease (>10 Fold) | Approved | 27466418 |
| DrugRepV_0292 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Real-time PCR | Decrease (0.59 Log10 Copies/GAPDH) | Approved | 26198719 |
| DrugRepV_0293 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Immunohistochemical assay | Decrease (>90 %) | Approved | 26198719 |
| DrugRepV_0329 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0336 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0349 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Ebola virus | Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus | NA | Renilla luciferase assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0396 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0410 | Sorafenib Tosylate | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0411 | Sunitinib Malate | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0412 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0413 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0416 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0417 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0420 | Vinorelbine Tartrate Hydrate | Antineoplastic and Immunomodulating Agents | Breast cancer and non-small cell lung cancer (NSCLC) | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26041706 |
| DrugRepV_0424 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0430 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0448 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0451 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0457 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0475 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26041706 |
| DrugRepV_0476 | Vinorelbine | Antineoplastic and Immunomodulating Agents | Breast cancer and non-small cell lung cancer (NSCLC) | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0480 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Approved | 26041706 |
| DrugRepV_0486 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0505 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Investigational | 26041706 |
| DrugRepV_0506 | Vinorelbine | Antineoplastic and Immunomodulating Agents | Breast cancer and non-small cell lung cancer (NSCLC) | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0518 | Vinblastine | Antineoplastic and Immunomodulating Agents | Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma) | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0519 | Vinorelbine | Antineoplastic and Immunomodulating Agents | Breast cancer and non-small cell lung cancer (NSCLC) | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0520 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0523 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26038505 |
| DrugRepV_0524 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0528 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26038505 |
| DrugRepV_0532 | Daunorubicin | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0541 | Carfilzomib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0547 | Daunorubicin | Antineoplastic and Immunomodulating Agents | Microbial infections and cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0553 | Topotecan | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0554 | Bosutinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0570 | Gefitinib | Antineoplastic and Immunomodulating Agents | Non-small cell lung cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26038505 |
| DrugRepV_0573 | Nilotinib | Antineoplastic and Immunomodulating Agents | Leukemias | Chronic myeloid leukemia (CML) | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 26038505 |
| DrugRepV_0583 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0584 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0590 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV/Kik | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0591 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV/May | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0592 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | SUDV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0593 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | MARV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0594 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | RAVV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0598 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV/Kik | NA | Real-time PCR | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0599 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | SUDV | NA | Real-time PCR | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0600 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | MARV | NA | Real-time PCR | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0602 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | ma-EBOV | NA | NA | Increase | Approved, Investigational | 23785035 |
| DrugRepV_0604 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | VLP-GP | NA | Flow cytometry | Decrease (95 %) | Approved, Investigational | 23785035 |
| DrugRepV_0627 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (76 %) | Approved, Investigational | 23577127 |
| DrugRepV_0666 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved, Investigational | 23577127 |
| DrugRepV_0690 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved, Investigational | 23577127 |
| DrugRepV_0762 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (99.955 %) | Approved | 27476412 |
| DrugRepV_0763 | Idarubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Acute myeloid leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (100 %) | Approved | 27476412 |
| DrugRepV_0766 | Mercaptopurine Hydrate | Antineoplastic and Immunomodulating Agents | Acute lymphatic leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (99.425 %) | Approved | 27476412 |
| DrugRepV_0767 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (99.845 %) | Approved | 27476412 |
| DrugRepV_0768 | Tacrolimus | Antineoplastic and Immunomodulating Agents | Allogenic organ transplant (kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (100 %) | Approved | 27476412 |
| DrugRepV_0769 | Epirubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (99.23 %) | Approved | 27476412 |
| DrugRepV_0770 | Fingolimod | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (99.18 %) | Approved | 27476412 |
| DrugRepV_0774 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (98.03 %) | Approved | 27476412 |
| DrugRepV_0777 | Azathioprine | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis. | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (96.385 %) | Approved | 27476412 |
| DrugRepV_0778 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (95.295 %) | Approved | 27476412 |
| DrugRepV_0788 | Sorafenib Tosylate | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (82.225 %) | Approved, Investigational | 27476412 |
| DrugRepV_0789 | Ethinyl estradiol | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (77.81 %) | Approved | 27476412 |
| DrugRepV_0792 | Sunitinib Malate | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (73.145 %) | Approved, Investigational | 27476412 |
| DrugRepV_0795 | Paclitaxel | Antineoplastic and Immunomodulating Agents | Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (78.59 %) | Approved | 27476412 |
| DrugRepV_0796 | Docetaxel | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (79.61 %) | Approved | 27476412 |
| DrugRepV_0805 | Pazopanib Hydrochloride | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (70.75 %) | Approved | 27476412 |
| DrugRepV_0807 | Vinorelbine | Antineoplastic and Immunomodulating Agents | Breast cancer and non-small cell lung cancer (NSCLC) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (67.24 %) | Approved | 27476412 |
| DrugRepV_0808 | Vorinostat | Antineoplastic and Immunomodulating Agents | T-cell lymphoma (CTCL, a type of cancer) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (70.85 %) | Approved | 27476412 |
| DrugRepV_0810 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (69.51 %) | Approved | 27476412 |
| DrugRepV_0813 | Nilotinib | Antineoplastic and Immunomodulating Agents | Leukemias | Chronic myeloid leukemia (CML) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (63.05 %) | Approved, Investigational | 27476412 |
| DrugRepV_0819 | Vinblastine Sulfate | Antineoplastic and Immunomodulating Agents | Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (66.755 %) | Approved | 27476412 |
| DrugRepV_0831 | Mitomycin C | Antineoplastic and Immunomodulating Agents | Malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (64.305 %) | Approved | 27476412 |
| DrugRepV_0833 | Doxorubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (65.365 %) | Approved | 27476412 |
| DrugRepV_0837 | Exemestane | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (61.61 %) | Approved | 27476412 |
| DrugRepV_0842 | Clofarabine | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (62.94 %) | Approved | 27476412 |
| DrugRepV_0853 | Vincristine Sulfate | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (62.91 %) | Approved, Investigational | 27476412 |
| DrugRepV_0885 | Procarbazine Hydrochloride | Antineoplastic and Immunomodulating Agents | Hodgkin's disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.4 %) | Approved | 27476412 |
| DrugRepV_0916 | Methyl Aminolevulinate Hydrochloride | Antineoplastic and Immunomodulating Agents | Non-hyperkeratotic actinic keratoses | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.34 %) | Approved | 27476412 |
| DrugRepV_0931 | Nilutamide | Antineoplastic and Immunomodulating Agents | Metastatic prostate cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.885 %) | Approved, Investigational | 27476412 |
| DrugRepV_0965 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.69 %) | Approved | 27476412 |
| DrugRepV_1004 | Estramustine phosphate Sodium | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.96 %) | Approved | 27476412 |
| DrugRepV_1005 | Goserelin Acetate | Antineoplastic and Immunomodulating Agents | Prostate cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.315 %) | Approved | 27476412 |
| DrugRepV_1011 | Pemetrexed Disodium | Antineoplastic and Immunomodulating Agents | Cancer (Chemotherapy drug) | Malignant pleural mesothelioma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (53.02 %) | Approved, Investigational | 27476412 |
| DrugRepV_1014 | Fulvestrant | Antineoplastic and Immunomodulating Agents | Breast cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.615 %) | Approved, Investigational | 27476412 |
| DrugRepV_1024 | Arsenic Trioxide | Antineoplastic and Immunomodulating Agents | Acute promyelocytic leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.425 %) | Approved | 27476412 |
| DrugRepV_1031 | Thalidomide | Antineoplastic and Immunomodulating Agents | Erythema nodosum leprosum | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.365 %) | Approved, Investigational, Withdrawn | 27476412 |
| DrugRepV_1036 | Dacarbazine | Antineoplastic and Immunomodulating Agents | Hodgkin disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.515 %) | Approved | 27476412 |
| DrugRepV_1049 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.075 %) | Approved | 27476412 |
| DrugRepV_1066 | Lomustine | Antineoplastic and Immunomodulating Agents | Brain tumor | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.175 %) | Approved, Investigational | 27476412 |
| DrugRepV_1080 | Pentostatin | Antineoplastic and Immunomodulating Agents | Hairy cell leukaemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.995 %) | Approved, Investigational | 27476412 |
| DrugRepV_1093 | Daunorubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (72.65 %) | Approved | 27476412 |
| DrugRepV_1099 | Cisplatin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.65 %) | Approved | 27476412 |
| DrugRepV_1142 | Decitabine | Antineoplastic and Immunomodulating Agents | Myelodysplastic syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.315 %) | Approved | 27476412 |
| DrugRepV_1160 | Anastrozole | Antineoplastic and Immunomodulating Agents | Breast cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.01 %) | Approved | 27476412 |
| DrugRepV_1202 | Flutamide | Antineoplastic and Immunomodulating Agents | Prostate cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.23 %) | Approved, Investigational | 27476412 |
| DrugRepV_1211 | Ifosfamide | Antineoplastic and Immunomodulating Agents | Germ cell testicular cancer | Cervical cancer | Osteosarcoma | Bladder cancer | Ovarian cancer | Small cell lung cancer | Non-Hodgkin's lymphoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.825 %) | Approved | 27476412 |
| DrugRepV_1213 | Cyclophosphamide Monohydrate | Antineoplastic and Immunomodulating Agents | Lymphoma and leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.745 %) | Approved | 27476412 |
| DrugRepV_1221 | Aminolevulinic Acid Hydrochloride | Antineoplastic and Immunomodulating Agents | Actinic keratosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.19 %) | Approved | 27476412 |
| DrugRepV_1230 | Temozolomide | Antineoplastic and Immunomodulating Agents | Anaplastic astrocytoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (52.52 %) | Approved | 27476412 |
| DrugRepV_1232 | Busulfan | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.405 %) | Approved | 27476412 |
| DrugRepV_1243 | Fluorouracil | Antineoplastic and Immunomodulating Agents | Multiple actinic or solar keratoses | Cancer, such as colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.195 %) | Approved | 27476412 |
| DrugRepV_1257 | Streptozocin | Antineoplastic and Immunomodulating Agents | Malignant neoplasms of pancreas (metastatic islet cell carcinoma) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.225 %) | Approved, Investigational | 27476412 |
| DrugRepV_1287 | Bicalutamide | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.37 %) | Approved | 27476412 |
| DrugRepV_1298 | Hydroxyurea | Antineoplastic and Immunomodulating Agents | Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (42.375 %) | Approved | 27476412 |
| DrugRepV_1313 | Carmustine | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.895 %) | Approved | 27476412 |
| DrugRepV_1318 | Carboplatin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.525 %) | Approved | 27476412 |
| DrugRepV_1319 | Gefitinib | Antineoplastic and Immunomodulating Agents | Non-small cell lung cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.195 %) | Approved, Investigational | 27476412 |
| DrugRepV_1327 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.81 %) | Approved | 27476412 |
| DrugRepV_1338 | Lenalidomide | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.155 %) | Approved | 27476412 |
| DrugRepV_1339 | Bleomycin Sulfate | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.675 %) | Approved | 27476412 |
| DrugRepV_1345 | Anagrelide | Antineoplastic and Immunomodulating Agents | Thrombocytosis and chronic myeloid leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.7 %) | Approved | 27476412 |
| DrugRepV_1383 | Altretamine | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.56 %) | Approved | 27476412 |
| DrugRepV_1411 | Topotecan Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.14 %) | Approved, Investigational | 27476412 |
| DrugRepV_1415 | Capecitabine | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.405 %) | Approved | 27476412 |
| DrugRepV_1418 | Letrozole | Antineoplastic and Immunomodulating Agents | Breast cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.705 %) | Approved, Investigational | 27476412 |
| DrugRepV_1434 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.89 %) | Approved, Investigational | 27476412 |
| DrugRepV_1437 | Bendamustine Hydrochloride | Antineoplastic and Immunomodulating Agents | Chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.125 %) | Approved | 27476412 |
| DrugRepV_1439 | Triptorelin Acetate | Antineoplastic and Immunomodulating Agents | Advanced prostate cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.535 %) | Approved | 27476412 |
| DrugRepV_1448 | Chlorambucil | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.315 %) | Approved | 27476412 |
| DrugRepV_1451 | Nelarabine | Antineoplastic and Immunomodulating Agents | T-cell acute lymphoblastic leukemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.83 %) | Approved, Investigational | 27476412 |
| DrugRepV_1458 | Mechlorethamine Hydrochloride | Antineoplastic and Immunomodulating Agents | Hodgkin's disease | Lymphosarcoma | Chronic myelocytic or chronic lymphocytic leukemia | Polycythemia vera | Mycosis fungoides | Bronchogenic carcinoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (39.89 %) | Approved, Investigational | 27476412 |
| DrugRepV_1469 | Thiotepa | Antineoplastic and Immunomodulating Agents | Breast cancer | Ovarian cancer | Bladder cancer | Bone marrow transplantation | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (39.125 %) | Approved, Investigational | 27476412 |
| DrugRepV_1471 | Cytarabine | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.14 %) | Approved | 27476412 |
| DrugRepV_1475 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (41.475 %) | Approved | 27476412 |
| DrugRepV_1479 | Etoposide | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.21 %) | Approved | 27476412 |
| DrugRepV_1487 | Mitotane | Antineoplastic and Immunomodulating Agents | Adrenocortical tumours | Cushing's syndrome | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (41.98 %) | Approved | 27476412 |
| DrugRepV_1493 | Sirolimus | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressant) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.38 %) | Approved, Investigational | 27476412 |
| DrugRepV_1494 | Melphalan | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Palliation of non-resectable epithelial carcinoma of the ovary | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (39.86 %) | Approved | 27476412 |
| DrugRepV_1499 | Lapatinib Ditosylate | Antineoplastic and Immunomodulating Agents | Breast cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (37.875 %) | Approved, Investigational | 27476412 |
| DrugRepV_1503 | Everolimus | Antineoplastic and Immunomodulating Agents | Immune disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (33.77 %) | Approved | 27476412 |
| DrugRepV_1504 | Oxaliplatin | Antineoplastic and Immunomodulating Agents | Colon Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (39.1 %) | Approved, Investigational | 27476412 |
| DrugRepV_1512 | Fludarabine phosphate | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (37.445 %) | Approved | 27476412 |
| DrugRepV_1519 | Cladribine | Antineoplastic and Immunomodulating Agents | Lymphoproliferative diseases | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (31.775 %) | Approved | 27476412 |
| DrugRepV_1521 | Irinotecan Hydrochloride | Antineoplastic and Immunomodulating Agents | Colorectal cancer | Small cell lung cancer | Cervical cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (30.47 %) | Approved, Investigational | 27476412 |
| DrugRepV_1523 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (29.485 %) | Approved, Investigational | 27476412 |
| DrugRepV_1524 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (26.615 %) | Approved | 27476412 |
| DrugRepV_1525 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (27.085 %) | Approved | 27476412 |
| DrugRepV_1528 | Temsirolimus | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (20.73 %) | Approved | 27476412 |
| DrugRepV_1533 | Mitoxantrone Hydrochloride | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (0.635 %) | Approved, Investigational | 27476412 |
| DrugRepV_1537 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1540 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1543 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1548 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | DAK_41525 | NA | Flow cytometry | Decrease (60 %) | Approved | 27476412 |
| DrugRepV_1553 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Zika virus | DAK_41525 | NA | Flow cytometry | Decrease (>80 %) | Approved | 27476412 |
| DrugRepV_1556 | Azathioprine | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis. | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | No significant effect | Approved | 27476412 |
| DrugRepV_1558 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1562 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (93 %) | Approved, Investigational | 26217313 |
| DrugRepV_1563 | Masitinib | Antineoplastic and Immunomodulating Agents | Mast cell tumors in dogs | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (84 %) | Investigational, Vet approved | 26217313 |
| DrugRepV_1565 | Pazopanib Hydrochloride | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 26217313 |
| DrugRepV_1566 | Paclitaxel | Antineoplastic and Immunomodulating Agents | Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (78 %) | Approved | 26217313 |
| DrugRepV_1567 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 26217313 |
| DrugRepV_1568 | Docetaxel | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (45 %) | Approved | 26217313 |
| DrugRepV_1569 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (72 %) | Approved, Investigational | 26217313 |
| DrugRepV_1570 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (68 %) | Approved | 26217313 |
| DrugRepV_1571 | Fulvestrant | Antineoplastic and Immunomodulating Agents | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (43 %) | Approved, Investigational | 26217313 |
| DrugRepV_1574 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (86 %) | Approved | 26217313 |
| DrugRepV_1575 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (57 %) | Approved | 26217313 |
| DrugRepV_1583 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 to 3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1584 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 to 3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1585 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rZH548 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1586 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 26217313 |
| DrugRepV_1587 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (50 %) | Approved, Investigational | 26217313 |
| DrugRepV_1588 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | NA | NA | Real-time PCR | Decrease | Approved, Investigational | 26217313 |
| DrugRepV_1589 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (90 %) | Approved, Investigational | 26217313 |
| DrugRepV_1590 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Luciferase reporter assay | Decrease (90 %) | Approved, Investigational | 26217313 |
| DrugRepV_1591 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1593 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4.5 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1595 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (1 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1597 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1599 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (5 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1601 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1603 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1605 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1607 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (93 %) | Approved, Investigational | 26217313 |
| DrugRepV_1609 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (97 %) | Approved, Investigational | 26217313 |
| DrugRepV_1610 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Survival assay | No significant effect | Approved, Investigational | 26217313 |
| DrugRepV_1611 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Real-time PCR | Decrease (2 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1612 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Real-time PCR | Decrease (2 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1613 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Real-time PCR | Decrease (0.4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1614 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Plaque assay | Decrease (1.9 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1650 | Teriflunomide | Antineoplastic and Immunomodulating Agents | Multiple sclerosis (MS) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1657 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Investigational | 27571349 |
| DrugRepV_1686 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1692 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1721 | Teriflunomide | Antineoplastic and Immunomodulating Agents | Multiple sclerosis (MS) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1728 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Investigational | 27571349 |
| DrugRepV_1757 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1763 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1792 | Teriflunomide | Antineoplastic and Immunomodulating Agents | Multiple sclerosis (MS) | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1799 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved, Investigational | 27571349 |
| DrugRepV_1828 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1834 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1912 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | PLCal_ZV | NA | MTT assay | Decrease (50 %) | Approved | 29315671 |
| DrugRepV_1915 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | PLCal_ZV | NA | Plaque assay | Decrease (50 %) | Approved | 29315671 |
| DrugRepV_1918 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | PLCal_ZV | NA | Time of addition assay | Decrease (90 %) | Approved | 29315671 |
| DrugRepV_1921 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | PLCal_ZV | NA | Real-time PCR | Decrease (85.7 %) | Approved | 29315671 |
| DrugRepV_1924 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | PLCal_ZV | NA | MTT assay | Decrease (62.5 %) | Approved | 29315671 |
| DrugRepV_1964 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (70 %) | Approved, Investigational | 28794043 |
| DrugRepV_1972 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1973 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1974 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1978 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1990 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1991 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1997 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1998 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1999 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_2013 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2014 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (90 %) | Approved | 24841273 |
| DrugRepV_2016 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 26585243 |
| DrugRepV_2018 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved, Investigational | 26585243 |
| DrugRepV_2171 | Lonidamine | Antineoplastic and Immunomodulating Agents | Benign prostatic hyperplasia | Prostate disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (35.3539647 %) | Investigational | 27742486 |
| DrugRepV_2178 | Mitoxantrone Hydrochloride | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (15.1626877 %) | Approved, Investigational | 27742486 |
| DrugRepV_2179 | Irinotecan Hydrochloride Trihydrate | Antineoplastic and Immunomodulating Agents | Colorectal cancer | Small cell lung cancer | Cervical cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.6383286 %) | Approved, Investigational | 27742486 |
| DrugRepV_2186 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (12.7697585 %) | Approved | 27742486 |
| DrugRepV_2196 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.2727802 %) | Approved | 27742486 |
| DrugRepV_2203 | Vorinostat | Antineoplastic and Immunomodulating Agents | T-cell lymphoma (CTCL, a type of cancer) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.83658563 %) | Approved | 27742486 |
| DrugRepV_2224 | Anastrozole | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.12964085 %) | Approved | 27742486 |
| DrugRepV_2226 | Gefitinib | Antineoplastic and Immunomodulating Agents | Non-small cell lung cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.05142618 %) | Approved, Investigational | 27742486 |
| DrugRepV_2227 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.04365539 %) | Investigational | 27742486 |
| DrugRepV_2228 | Fulvestrant | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.04032324 %) | Approved, Investigational | 27742486 |
| DrugRepV_2232 | Lapatinib Ditosylate | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.93254343 %) | Approved, Investigational | 27742486 |
| DrugRepV_2243 | 5-Aminolevulinic Acid Hydrochloride | Antineoplastic and Immunomodulating Agents | Actinic keratoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.19454622 %) | Approved | 27742486 |
| DrugRepV_2247 | Sunitinib Malate | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.08231961 %) | Approved, Investigational | 27742486 |
| DrugRepV_2276 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.92265574 %) | Approved, Investigational | 27742486 |
| DrugRepV_2285 | Aminoglutethimide | Antineoplastic and Immunomodulating Agents | Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast. | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.69804317 %) | Approved | 27742486 |
| DrugRepV_2288 | Erlotinib Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.66114654 %) | Approved | 27742486 |
| DrugRepV_2290 | Ifosfamide | Antineoplastic and Immunomodulating Agents | Germ cell testicular cancer | Cervical cancer | Osteosarcoma | Bladder cancer | Ovarian cancer | Small cell lung cancer | Non-Hodgkin's lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.62298755 %) | Approved | 27742486 |
| DrugRepV_2298 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.41764454 %) | Approved | 27742486 |
| DrugRepV_2306 | Pemetrexed | Antineoplastic and Immunomodulating Agents | Cancer (Chemotherapy drug) | Malignant pleural mesothelioma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.33026007 %) | Approved, Investigational | 27742486 |
| DrugRepV_2317 | Cytarabine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.9061166 %) | Approved | 27742486 |
| DrugRepV_2318 | Lenalidomide | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.87586362 %) | Approved | 27742486 |
| DrugRepV_2319 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.85778554 %) | Approved | 27742486 |
| DrugRepV_2322 | Hydroxyurea | Antineoplastic and Immunomodulating Agents | Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.83370655 %) | Approved | 27742486 |
| DrugRepV_2325 | Lapatinib | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.71161747 %) | Approved, Investigational | 27742486 |
| DrugRepV_2346 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.27014953 %) | Approved | 27742486 |
| DrugRepV_2353 | Etoposide | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.1881398 %) | Approved | 27742486 |
| DrugRepV_2375 | Bicalutamide | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.5677801 %) | Approved | 27742486 |
| DrugRepV_2378 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.53351293 %) | Approved | 27742486 |
| DrugRepV_2393 | Cyclophosphamide Monohydrate | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.30836213 %) | Approved | 27742486 |
| DrugRepV_2395 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.2767148 %) | Investigational | 27742486 |
| DrugRepV_2408 | Decitabine | Antineoplastic and Immunomodulating Agents | Myelodysplastic syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.12473547 %) | Approved | 27742486 |
| DrugRepV_2411 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.0549399 %) | Approved | 27742486 |
| DrugRepV_2417 | Mitotane | Antineoplastic and Immunomodulating Agents | Adrenocortical tumours | Cushing's syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.940259 %) | Approved | 27742486 |
| DrugRepV_2420 | Altretamine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.89361145 %) | Approved | 27742486 |
| DrugRepV_2436 | Lomustine | Antineoplastic and Immunomodulating Agents | Brain tumor | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.46226348 %) | Approved, Investigational | 27742486 |
| DrugRepV_2450 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.05561841 %) | Approved | 27742486 |
| DrugRepV_2456 | Masitinib | Antineoplastic and Immunomodulating Agents | Mast cell tumors in dogs | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.95794841 %) | Investigational, Vet approved | 27742486 |
| DrugRepV_2472 | Anagrelide Hydrochloride | Antineoplastic and Immunomodulating Agents | Thrombocytosis and chronic myeloid leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.62449045 %) | Approved | 27742486 |
| DrugRepV_2483 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.33541797 %) | Approved | 27742486 |
| DrugRepV_2484 | Dacarbazine | Antineoplastic and Immunomodulating Agents | Hodgkin disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.32719355 %) | Approved | 27742486 |
| DrugRepV_2497 | Procarbazine Hydrochloride | Antineoplastic and Immunomodulating Agents | Hodgkin's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.16145424 %) | Approved | 27742486 |
| DrugRepV_2506 | Nelarabine | Antineoplastic and Immunomodulating Agents | T-cell acute lymphoblastic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.02495853 %) | Approved, Investigational | 27742486 |
| DrugRepV_2529 | Axitinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5090732 %) | Approved | 27742486 |
| DrugRepV_2534 | Vandetanib | Antineoplastic and Immunomodulating Agents | Medullary thyroid cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.588259 %) | Approved | 27742486 |
| DrugRepV_2536 | Paclitaxel | Antineoplastic and Immunomodulating Agents | Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6093096 %) | Approved | 27742486 |
| DrugRepV_2549 | Diethylstilbestrol | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.85143 %) | Approved | 27742486 |
| DrugRepV_2567 | Pralatrexate | Antineoplastic and Immunomodulating Agents | T-cell lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.1883229 %) | Approved, Investigational | 27742486 |
| DrugRepV_2571 | Bendamustine Hydrochloride | Antineoplastic and Immunomodulating Agents | Chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2429281 %) | Approved | 27742486 |
| DrugRepV_2586 | Bleomycin Sulfate | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3921953 %) | Approved | 27742486 |
| DrugRepV_2589 | Irinotecan | Antineoplastic and Immunomodulating Agents | Colorectal cancer | Small cell lung cancer | Cervical cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4109846 %) | Approved, Investigational | 27742486 |
| DrugRepV_2591 | Thalidomide | Antineoplastic and Immunomodulating Agents | Erythema nodosum leprosum | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.433969 %) | Approved, Investigational, Withdrawn | 27742486 |
| DrugRepV_2597 | Letrozole | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5283999 %) | Approved, Investigational | 27742486 |
| DrugRepV_2602 | Topotecan Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5991588 %) | Approved, Investigational | 27742486 |
| DrugRepV_2608 | Exemestane | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6612547 %) | Approved | 27742486 |
| DrugRepV_2613 | Azathioprine | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis. | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.720627 %) | Approved | 27742486 |
| DrugRepV_2614 | Fludarabine | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7238787 %) | Approved | 27742486 |
| DrugRepV_2617 | Cisplatin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7493506 %) | Approved | 27742486 |
| DrugRepV_2638 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0019627 %) | Approved | 27742486 |
| DrugRepV_2646 | Pazopanib Hydrochloride | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1099434 %) | Approved | 27742486 |
| DrugRepV_2651 | Clafen | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1776836 %) | Approved | 27742486 |
| DrugRepV_2656 | Fludarabine phosphate | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2595351 %) | Approved | 27742486 |
| DrugRepV_2659 | Carboplatin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3400754 %) | Approved | 27742486 |
| DrugRepV_2670 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4398466 %) | Approved | 27742486 |
| DrugRepV_2672 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.47799 %) | Approved, Investigational | 27742486 |
| DrugRepV_2679 | Temsirolimus | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.55968 %) | Approved | 27742486 |
| DrugRepV_2684 | Cladribine | Antineoplastic and Immunomodulating Agents | Lymphoproliferative diseases | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.6030286 %) | Approved | 27742486 |
| DrugRepV_2690 | Capecitabine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.7889064 %) | Approved | 27742486 |
| DrugRepV_2696 | Nilotinib | Antineoplastic and Immunomodulating Agents | Leukemias | Chronic myeloid leukemia (CML) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9152275 %) | Approved, Investigational | 27742486 |
| DrugRepV_2707 | Vinblastine | Antineoplastic and Immunomodulating Agents | Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0262855 %) | Approved | 27742486 |
| DrugRepV_2716 | Abiraterone Acetate | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.222047 %) | Approved | 27742486 |
| DrugRepV_2718 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2495137 %) | Approved, Investigational | 27742486 |
| DrugRepV_2723 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.356697 %) | Approved | 27742486 |
| DrugRepV_2732 | Adrucil | Antineoplastic and Immunomodulating Agents | Multiple actinic or solar keratoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4729205 %) | Approved | 27742486 |
| DrugRepV_2758 | Mercaptopurine | Antineoplastic and Immunomodulating Agents | Acute lymphatic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.11069 %) | Approved | 27742486 |
| DrugRepV_2760 | Streptozotocin | Antineoplastic and Immunomodulating Agents | Malignant neoplasms of pancreas (metastatic islet cell carcinoma) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1556333 %) | Approved, Investigational | 27742486 |
| DrugRepV_2767 | Oxaliplatin | Antineoplastic and Immunomodulating Agents | Colon Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.2965612 %) | Approved, Investigational | 27742486 |
| DrugRepV_2771 | Methazolastone | Antineoplastic and Immunomodulating Agents | Refractory anaplastic astrocytoma | Glioblastoma multiforme | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4157601 %) | Approved, Investigational | 27742486 |
| DrugRepV_2776 | Ethinyl estradiol | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4808177 %) | Approved | 27742486 |
| DrugRepV_2798 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.9388504 %) | Approved | 27742486 |
| DrugRepV_2802 | Idarubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Acute myeloid leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.0284839 %) | Approved | 27742486 |
| DrugRepV_2805 | Plerixafor octahydrochloride | Antineoplastic and Immunomodulating Agents | Mobilization of hematopoietic stem cells | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.1063153 %) | Approved | 27742486 |
| DrugRepV_2806 | Docetaxel | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.1241227 %) | Approved | 27742486 |
| DrugRepV_2816 | Clofarabine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4343488 %) | Approved | 27742486 |
| DrugRepV_2824 | Cabazitaxel | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.6935891 %) | Approved | 27742486 |
| DrugRepV_2837 | Pazopanib | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2172761 %) | Approved | 27742486 |
| DrugRepV_2838 | Romidepsin | Antineoplastic and Immunomodulating Agents | T-cell lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2173849 %) | Approved, Investigational | 27742486 |
| DrugRepV_2842 | Abitrexate | Antineoplastic and Immunomodulating Agents | Gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and acute lymphocytic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.3272062 %) | Approved | 27742486 |
| DrugRepV_2864 | Epirubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2856781 %) | Approved | 27742486 |
| DrugRepV_2871 | Daunorubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.6172048 %) | Approved | 27742486 |
| DrugRepV_2881 | Doxorubicin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.2310876 %) | Approved | 27742486 |
| DrugRepV_2921 | Busulfan | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.084498 %) | Approved | 27742486 |
| DrugRepV_2983 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | CHIKV replicon | NA | EGFP assay | Decrease (50 %) | Approved | 22205980 |
| DrugRepV_2992 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | CHIKV replicon | NA | Rluc assay | Decrease (50 %) | Approved | 22205980 |
| DrugRepV_3093 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.82 %) | Approved | 23275491 |
| DrugRepV_3105 | Bleomycin | Antineoplastic and Immunomodulating Agents | Bacterial infection and cancer | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (99.27 %) | Approved | 23275491 |
| DrugRepV_3116 | Daunorubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Leukemia | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (95.56 %) | Approved | 23275491 |
| DrugRepV_3122 | Vinblastine Sulfate | Antineoplastic and Immunomodulating Agents | Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma) | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (93.75 %) | Approved | 23275491 |
| DrugRepV_3128 | Mithramycin A | Antineoplastic and Immunomodulating Agents | Testicular cancer | Hypercalcemia | Hypercalciuria | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (87.96 %) | Approved | 23275491 |
| DrugRepV_3129 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | CHIKV-0708 | NA | Immunoflourescence assay | Decrease (86.92 %) | Approved | 23275491 |
| DrugRepV_3135 | Daunorubicin | Antineoplastic and Immunomodulating Agents | Leukemia | Chikungunya virus | CHIKV-0708 | NA | Plaque assay | Decrease (50 %) | Approved | 23275491 |
| DrugRepV_3138 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | Chikungunya virus | CHIKV-122508 | NA | Plaque assay | Decrease (4.3 Log) | Approved, Investigational | 23275491 |
| DrugRepV_3139 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | Chikungunya virus | CHIKV-0708 | NA | Plaque assay | Decrease (2.3 Log) | Approved, Investigational | 23275491 |
| DrugRepV_3162 | IFN-alpha2a | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 14670584 |
| DrugRepV_3163 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 14670584 |
| DrugRepV_3167 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (5.4 Log) | Approved | 14670584 |
| DrugRepV_3171 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Chikungunya virus | Ross C347 | NA | Cytopathic effect (CPE) assay | Decrease (99 %) | Approved | 14670584 |
| DrugRepV_3173 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 21070810 |
| DrugRepV_3174 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 21070810 |
| DrugRepV_3175 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 21070810 |
| DrugRepV_3176 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 21070810 |
| DrugRepV_3177 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 21070810 |
| DrugRepV_3178 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Plaque assay | Decrease | Approved | 21070810 |
| DrugRepV_3179 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Real-time PCR | Decrease | Approved | 21070810 |
| DrugRepV_3180 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | DRDE-06 | NA | Real-time PCR | Decrease | Approved | 21070810 |
| DrugRepV_3288 | Pazopanib | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3289 | Axitinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3291 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27177310 |
| DrugRepV_3329 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | WSN/H1N1 |  | Plaque assay | Decrease (99 %) | Approved | 29990517 |
| DrugRepV_3330 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | FPV/H7N7 | | Plaque assay | Decrease (99 %) | Approved | 29990517 |
| DrugRepV_3331 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | RB1/H1N1pdm09 | | Plaque assay | Decrease (50 %) | Approved | 29990517 |
| DrugRepV_3332 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | PR8M/H1N1 | | Plaque assay | No significant effect (0.3 Log) | Approved | 29990517 |
| DrugRepV_3333 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | Victoria/H3N2 | | Plaque assay | Decrease (1.2 Log) | Approved | 29990517 |
| DrugRepV_3334 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | FPV/H7N7 | | Plaque assay | Decrease (1 Log) | Approved | 29990517 |
| DrugRepV_3335 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | WSN/H1N1 | | Plaque assay | Decrease (98 %) | Approved | 29990517 |
| DrugRepV_3336 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | Victoria/H3N2 | | Plaque assay | Decrease (76 %) | Approved | 29990517 |
| DrugRepV_3337 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | FPV/H7N7 | | Plaque assay | Decrease (80 %) | Approved | 29990517 |
| DrugRepV_3338 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | WSN/H1N1 | | Plaque assay | No significant effect (0.8 Log) | Approved | 29990517 |
| DrugRepV_3339 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | WSN/H1N1 | | Plaque assay | Decrease (70 %) | Approved | 29990517 |
| DrugRepV_3340 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | Victoria/H3N2 | | Plaque assay | Decrease (70 %) | Approved | 29990517 |
| DrugRepV_3341 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | FPV/H7N7 | | Plaque assay | Decrease (100 %) | Approved | 29990517 |
| DrugRepV_3342 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | WSN/H1N1 | | Plaque assay | No significant effect (0.8 Log) | Approved | 29990517 |
| DrugRepV_3343 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | Victoria/H3N2 | | Plaque assay | No significant effect (0.5 Log) | Approved | 29990517 |
| DrugRepV_3344 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | KAN-1/H5N1 | | Plaque assay | Decrease (98 %) | Approved | 29990517 |
| DrugRepV_3345 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | Mallard/H5N1 | | Plaque assay | Decrease (99 %) | Approved | 29990517 |
| DrugRepV_3346 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | SC35M/H7N7 | | Plaque assay | Decrease (90 %) | Approved | 29990517 |
| DrugRepV_3347 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | KAN-1/H5N1 | | Plaque assay | Decrease (1.2 Log) | Approved | 29990517 |
| DrugRepV_3348 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | SC35M/H7N7 | | Plaque assay | No significant effect (0.8 Log) | Approved | 29990517 |
| DrugRepV_3353 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | RB1/H1N1pdm09 | | Plaque assay | Decrease (1.5 Log) | Approved | 29990517 |
| DrugRepV_3354 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | RB1/H1N1pdm09 | | Plaque assay | Decrease (98 %) | Approved | 29990517 |
| DrugRepV_3355 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | RB1/H1N1pdm09 | | Survival assay | Decrease | Approved | 29990517 |
| DrugRepV_3363 | Peg-interferon A-2b | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | HKU-39849 | NA | Cytopathic effect (CPE) assay | Decrease (100 %) | Approved | 23620378 |
| DrugRepV_3364 | Peg-interferon A-2b | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Middle East respiratory syndrome coronavirus | HKU-39849 | NA | Cytopathic effect (CPE) assay | Decrease (100 %) | Approved | 23620378 |
| DrugRepV_3365 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Influenza virus | A/ WSN/1933 (H1N1) | | High-throughput screening | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3371 | Mercaptopurine | Antineoplastic and Immunomodulating Agents | Acute lymphatic leukemia | Influenza virus | A/ WSN/1933 (H1N1) | | High-throughput screening | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3375 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3378 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3379 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3380 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3381 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3383 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3385 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3386 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3387 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3388 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3389 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3391 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3392 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3393 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3394 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3395 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3397 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3398 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3399 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>1 Log) | Approved | 24096239 |
| DrugRepV_3400 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>3 Log) | Approved | 24096239 |
| DrugRepV_3401 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (100 %) | Approved | 24096239 |
| DrugRepV_3403 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (100 %) | Approved | 24096239 |
| DrugRepV_3404 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (76.2 %) | Approved | 24096239 |
| DrugRepV_3405 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (70.2 %) | Approved | 24096239 |
| DrugRepV_3406 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (66.6 %) | Approved | 24096239 |
| DrugRepV_3438 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Approved | 22910914 |
| DrugRepV_3440 | Carfilzomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Approved | 22910914 |
| DrugRepV_3441 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma and mantle cell lymphoma | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Approved | 22910914 |
| DrugRepV_3446 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Approved | 22910914 |
| DrugRepV_3448 | Carfilzomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Approved | 22910914 |
| DrugRepV_3449 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma and mantle cell lymphoma | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Approved | 22910914 |
| DrugRepV_3554 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | Asian strain | NA | Real-time PCR | Decrease (50 %) | Approved | 30455237 |
| DrugRepV_3555 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | Asian strain | NA | Yield reduction assay | Decrease (50 %) | Approved | 30455237 |
| DrugRepV_3571 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3574 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3575 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3576 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3577 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 30149038 |
| DrugRepV_3590 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV trVLP | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 30149038 |
| DrugRepV_3706 | Imatinib Methanesulfonate Salt | Antineoplastic and Immunomodulating Agents | NA | Marburg virus | NA | NA | NA | Decrease (99 %) | Approved | 24713118 |
| DrugRepV_3710 | Imatinib Methanesulfonate Salt | Antineoplastic and Immunomodulating Agents | NA | Ebola virus | NA | NA | NA | Decrease (95 %) | Approved | 24713118 |
| DrugRepV_4055 | Cyclosporine | Antineoplastic and Immunomodulating Agents | Immune disorders | Hendra virus | NA | NA | Immunolabeling assay | Decrease (50 %) | Approved | 20668647 |
| DrugRepV_4520 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 15200845 |
| DrugRepV_4521 | Multiferon | Antineoplastic and Immunomodulating Agents | Hepatitis (viral, C) | Leukemia | Melanoma | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 15200845 |
| DrugRepV_4522 | IFN-alpha2a | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved, Investigational | 15200845 |
| DrugRepV_4523 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4524 | IFN-alphan1 | Antineoplastic and Immunomodulating Agents | Venereal or genital warts caused by the Human Papiloma Virus | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (100 %) | Approved, Investigational | 15200845 |
| DrugRepV_4526 | IFN-beta1a | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Condyloma acuminatum | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved, Investigational | 15200845 |
| DrugRepV_4527 | IFN-beta1b | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (100 %) | Approved | 15200845 |
| DrugRepV_4655 | 5-Fluorouracil | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27909576 |
| DrugRepV_4726 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | Decrease | Approved | 29566060 |
| DrugRepV_4741 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (93 %) | Approved, Investigational | 25487801 |
| DrugRepV_4742 | Everolimus | Antineoplastic and Immunomodulating Agents | Immune disorders | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (57 %) | Approved | 25487801 |
| DrugRepV_4743 | Dabrafenib | Antineoplastic and Immunomodulating Agents | Melanoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | Approved | 25487801 |
| DrugRepV_4745 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (95 %) | Approved | 25487801 |
| DrugRepV_4746 | Miltefosine | Antineoplastic and Immunomodulating Agents | Visceral leishmaniasis | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (28 %) | Approved | 25487801 |
| DrugRepV_4773 | 6-Mercaptopurine | Antineoplastic and Immunomodulating Agents | Acute lymphatic leukemia | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 25542975 |
| DrugRepV_4774 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 25542975 |
| DrugRepV_4776 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 25542975 |
| DrugRepV_4777 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 24323636 |
| DrugRepV_4779 | IFN-beta | Antineoplastic and Immunomodulating Agents | NA | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | NA | 24323636 |
| DrugRepV_4780 | IFN-alpha2a | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 24323636 |
| DrugRepV_4781 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 24323636 |
| DrugRepV_4783 | IFN-gamma | Antineoplastic and Immunomodulating Agents | NA | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | NA | 24323636 |
| DrugRepV_5101 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 29024765 |
| DrugRepV_5109 | 5-Azacytidine | Antineoplastic and Immunomodulating Agents | Anemia | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (0 %) | Approved | 29024765 |
| DrugRepV_5124 | Gleevec | Antineoplastic and Immunomodulating Agents | Leukemia | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (26 %) | Approved | 29024765 |
| DrugRepV_5126 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | Decrease (99 %) | Approved | 29024765 |
| DrugRepV_5185 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5191 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5220 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (86.8 %) | Approved | 21994655 |
| DrugRepV_5222 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (91.1 %) | Approved | 21994655 |
| DrugRepV_5223 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | rMP12-rLuc | NA | Plaque assay | Decrease (>2 log pfu/ml) | Approved | 19197350 |
| DrugRepV_5224 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | MP12 | NA | Plaque assay | No significant effect (NA pfu/ml) | Approved | 19197350 |
| DrugRepV_5229 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | IbAr 10200 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5234 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | Spu 128/81 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5239 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | Hy-13 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5244 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | Crimean-Congo hemorrhagic fever virus | UG3010 | NA | Neutral red uptake assay | Decrease (50 %) | Experimental | 15026198 |
| DrugRepV_5361 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5362 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5363 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5364 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5365 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5366 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5367 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5368 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | Approved | 21616094 |
| DrugRepV_5369 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5370 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5371 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5372 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Lassa virus | AV | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5373 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5374 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5375 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5376 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Ebola virus | NA | NA | RT-PCR | Decrease (90 %) | Approved | 21616094 |
| DrugRepV_5407 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Lassa virus | Josiah | NA | Luciferase assay | Decrease (50 %) | Approved, Investigational | 30700611 |
| DrugRepV_5408 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | Mayinga | NA | Luciferase assay | Decrease (50 %) | Approved, Investigational | 30700611 |
| DrugRepV_5418 | Regorafenib | Antineoplastic and Immunomodulating Agents | Metastatic colorectal cancer (CRC) | Influenza virus | WSN | | WST-1 assay | Decrease (50 %) | Approved | 30883607 |
| DrugRepV_5419 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Influenza virus | WSN | | WST-1 assay | Decrease (50 %) | Approved, Investigational | 30883607 |
| DrugRepV_5471 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | FPV/H7N7 | | Plaque assay | No significant effect (2.5 Log) | Approved | 29990517 |
| DrugRepV_5472 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Influenza virus | Mallard/H5N1 | | Plaque assay | No significant effect (2 Log) | Approved | 29990517 |
| DrugRepV_5550 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5575 | Dabrafenib | Antineoplastic and Immunomodulating Agents | Melanoma | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5594 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | 276RKI, PRS41393 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_5595 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | 276RKI, PRS41393 | | Plaque assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_5596 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | TSV01, 429557, New Guinea C | | Plaque/ Luciferase assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_5597 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | TSV01, 429557, New Guinea C | | Plaque/ Luciferase assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_5598 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | Philippines/H87/1956 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_5599 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Philippines/H87/1956 | | Plaque assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_5600 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | BC287/97, H241 | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_5601 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | BC287/97, H241 | | Plaque assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_5602 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | N124D/K128E | | Real-time PCR | No significant effect | Approved, Investigational | 28240606 |
| DrugRepV_5603 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | N124D/K128E | | Real-time PCR | No significant effect | Approved | 28240606 |
| DrugRepV_5609 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (70 %) | Approved | 28099856 |
| DrugRepV_5610 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (90 %) | Approved | 28099856 |
| DrugRepV_5611 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (80 %) | Approved | 28099856 |
| DrugRepV_5621 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (60 %) | Approved | 28099856 |
| DrugRepV_5622 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (30 %) | Approved | 28099856 |
| DrugRepV_5623 | Cabozantinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (10 %) | Approved | 28099856 |
| DrugRepV_5656 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 872 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5657 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 2402 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5658 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | PVP41 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5659 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN3300 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5660 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN2928 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5661 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | ST | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5662 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 3295 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5663 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | PR8545 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5664 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | PR2167 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5665 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | PVP110 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5666 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 863 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5667 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 2930 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5668 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 2270 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5669 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EHI 69273 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5670 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EHI 16693 | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5675 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 3295 | | Immunohistochemical assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_5676 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Dengue virus | EDEN 3295 | | Real-time PCR | Decrease | Approved | 26565697 |
| DrugRepV_5700 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (50 %) | Approved | 12504563 |
| DrugRepV_5701 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (51 %) | Approved | 12504563 |
| DrugRepV_5702 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (52 %) | Approved | 12504563 |
| DrugRepV_5703 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (50 %) | Approved | 12504563 |
| DrugRepV_5704 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Plaque assay | Decrease (>1.0 + E3 pfu/ml) | Approved | 12504563 |
| DrugRepV_5705 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Real-time PCR | Decrease (>100 Fold) | Approved | 12504563 |
| DrugRepV_5706 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | N1047 | | Flow cytometry | Decrease (97 %) | Approved | 12504563 |
| DrugRepV_5711 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Dengue virus | NA | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 29753658 |
| DrugRepV_5712 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | NA | | Luciferase reporter assay | Decrease (50 %) | Approved | 29753658 |
| DrugRepV_5804 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | NA | | Immunoflourescence assay | Decrease (92.38 %) | Approved | 22155902 |
| DrugRepV_5813 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | NA | | Immunoflourescence assay | Decrease (59.6 %) | Approved | 22155902 |
| DrugRepV_5991 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea | | Plaque assay | Decrease (>2 Log (pfu/ml)) | Approved | 17360676 |
| DrugRepV_5992 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea | | Plaque assay | Decrease (>2 Log (pfu/ml)) | Approved | 17360676 |
| DrugRepV_5993 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea | | Plaque assay | Decrease (>2 Log (pfu/ml)) | Approved | 17360676 |
| DrugRepV_5994 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_5995 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_5996 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_5997 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | Clone | | Immunoflourescence assay | Decrease (>70 %) | Approved | 17360676 |
| DrugRepV_6020 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Focus forming assay | Decrease (90 %) | Approved | 23616652 |
| DrugRepV_6021 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Focus forming assay | Decrease (1 Log) | Approved | 23616652 |
| DrugRepV_6023 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Northern blot | Decrease (65 AU (Arbitrary units)) | Approved | 23616652 |
| DrugRepV_6025 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Northern blot | Decrease (75 AU (Arbitrary units)) | Approved | 23616652 |
| DrugRepV_6029 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Western blot | Decrease (Decrease expression of C protein Band Intensity) | Approved | 23616652 |
| DrugRepV_6030 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Western blot | Decrease (Decrease expression of E protein Band Intensity) | Approved | 23616652 |
| DrugRepV_6031 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Western blot | Decrease (Decrease expression of NS3 and NS5 protein Band Intensity) | Approved | 23616652 |
| DrugRepV_6033 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Luciferase reporter assay | No significant effect (0.4 Log) | Approved | 23616652 |
| DrugRepV_6034 | Aminolevullic acid | Antineoplastic and Immunomodulating Agents | NA | Dengue virus | 16681 | | Focus forming assay | Decrease (41.1 %) | NA | 30055216 |
| DrugRepV_6036 | Mitoxantrone hydrochloride | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Dengue virus | 16681 | | Focus forming assay | Decrease (53.8 %) | NA | 30055216 |
| DrugRepV_6096 | Doxorubicin | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C (NGC) | | qRT-PCR | Decrease (50 %) | Approved | 20837762 |
| DrugRepV_6137 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | DENV replicon assay | Decrease (50 %) | Approved | 29672522 |
| DrugRepV_6158 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | MTT assay | Decrease (50 %) | Approved | 22068705 |
| DrugRepV_6183 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C (NGC) | | Cell proliferation assay | Decrease (50 %) | Approved | 17662475 |
| DrugRepV_6317 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (92.38 %) | Approved | 22155902 |
| DrugRepV_6326 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (59.6 %) | Approved | 22155902 |
| DrugRepV_6481 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Human immunodeficiency virus | NL4-3 | | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_6482 | Erlotinib | Antineoplastic and Immunomodulating Agents | Cancer | Human immunodeficiency virus | NL4-3 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28240606 |
| DrugRepV_6483 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (60 %) | Approved | 26807966 |
| DrugRepV_6484 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (90 %) | Approved | 26807966 |
| DrugRepV_6494 | Decitabine | Antineoplastic and Immunomodulating Agents | Myelodysplastic syndrome | Human immunodeficiency virus | NA | | Plaque assay | Decrease (50 %) | Approved | 20610712 |
| DrugRepV_6495 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Human immunodeficiency virus | NA | | Plaque assay | Decrease (50 %) | Approved | 20610712 |
| DrugRepV_6497 | Hydroxyurea | Antineoplastic and Immunomodulating Agents | Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia | Human immunodeficiency virus | NA | | Plaque assay | Decrease (10 %) | Approved | 20610712 |
| DrugRepV_6499 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Human immunodeficiency virus | NA | | Plaque assay | Decrease (100 %) | Approved | 20610712 |
| DrugRepV_6538 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6539 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6540 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved | 24419350 |
| DrugRepV_6541 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved, Investigational | 24419350 |
| DrugRepV_6542 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6543 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6544 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved | 24419350 |
| DrugRepV_6545 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved, Investigational | 24419350 |
| DrugRepV_6546 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6547 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6548 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved | 24419350 |
| DrugRepV_6549 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved, Investigational | 24419350 |
| DrugRepV_6550 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | PHA+IL2 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6551 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | PHA+IL2 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6552 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | PHA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6553 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | PHA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6554 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | NA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6555 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | NA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6556 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | xxLAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6557 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | M184V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6558 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | K65R | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6559 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | L74V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6560 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | A62V/V75I/F77L/F116Y/Q151M | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6561 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | 4XAZT(D67N/K70R/T215Y/K219Q) | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6562 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | xxLAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6563 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | M184V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6564 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | K65R | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6565 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | L74V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6566 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | A62V/V75I/F77L/F116Y/Q151M | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6567 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | 4XAZT(D67N/K70R/T215Y/K219Q) | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_7003 | Sunitinib | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | West Nile virus | NY 99 3000.0259 | | Focus forming assay | Decrease (50 %) | Approved, Investigational | 28240606 |
| DrugRepV_7005 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Yellow fever virus | YF17D | | Plaque assay | Decrease (50 %) | Approved | 26565697 |
| DrugRepV_7006 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | 3000.0259 | | Plaque assay | Decrease (100 pfu/ml) | Approved | 12504563 |
| DrugRepV_7015 | Mitotane | Antineoplastic and Immunomodulating Agents | Adrenocortical tumours | Cushing's syndrome | Japanese encephalitis virus | AT31 | | Luciferase reporter assay | Decrease (50 %) | Approved | 28814523 |
| DrugRepV_7114 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Japanese encephalitis virus | P3 | | Survival assay | Increase | Approved | 30567313 |
| DrugRepV_7216 | Doxorubicin | Antineoplastic and Immunomodulating Agents | Cancer | Yellow fever virus | 17D | | qRT-PCR | Decrease (50 %) | Approved | 20837762 |
| DrugRepV_7443 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | New York | | Visual assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7444 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | Uganda strain B 956 | | Visual assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7451 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | West Nile virus | New York | | Visual assay | Decrease (50 %) | Experimental | 12076755 |
| DrugRepV_7455 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | New York | | NR assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7456 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | Uganda strain B 956 | | NR assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7463 | Tiazofurin | Antineoplastic and Immunomodulating Agents | Cancer | West Nile virus | New York | | NR assay | Decrease (50 %) | Experimental | 12076755 |
| DrugRepV_7493 | 5-Azacytidine | Antineoplastic and Immunomodulating Agents | Anemia | West Nile virus | New York | | Visual assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7498 | 5-Azacytidine | Antineoplastic and Immunomodulating Agents | Anemia | West Nile virus | New York | | NR assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7507 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | New York | | Visual assay | Decrease (50 %) | Approved | 12076755 |
| DrugRepV_7512 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | West Nile virus | New York | | Virus yield reduction assay | Decrease (90 %) | Approved | 12076755 |
| DrugRepV_7559 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | SARS Coronavirus-2 | BetaCoV/Hong Kong/VM20001061/2020 | NA | TCID50 assay/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7593 | Baricitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52283 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7594 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52291 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7595 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52291 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7600 | Abemaciclib | Antineoplastic And Immunomodulating Agents | Cancer | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7601 | Abemaciclib | Antineoplastic And Immunomodulating Agents | Cancer | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7606 | Gilteritinib | Antineoplastic and Immunomodulating Agents | Relapsed or refractory acute myeloid leukaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7607 | Gilteritinib | Antineoplastic and Immunomodulating Agents | Relapsed or refractory acute myeloid leukaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7613 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | SARS Coronavirus-2 | Wuhan/WIV04/2023 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7618 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52293 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7619 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52293 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7637 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52294 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7638 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52294 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7666 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7667 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7670 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Viral load reduction assay | Decrease (90 %) | Approved | 32473310 |
| DrugRepV_7671 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Viral load reduction assay | Decrease (90 %) | Approved | 32473310 |
| DrugRepV_7679 | Bosutinib | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7683 | Fedratinib | Antineoplastic And Immunomodulating Agents | Myelofibrosis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7684 | Gilteritinib | Antineoplastic And Immunomodulating Agents | Acute myeloid leukemia | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7691 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7702 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7703 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7704 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7777 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32687696 |
| DrugRepV_7915 | Mycophenolic acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Influenza virus | A/Puerto Rico/8/34 | | MTT assay | Decrease (50 %) | Approved | 31941776 |
| DrugRepV_7925 | Mycophenolic acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Influenza virus | B/Brisbane/60/08 | | MTT assay | Decrease (50 %) | Approved | 31941776 |
| DrugRepV_7933 | Mycophenolic acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Influenza virus | A/Puerto Rico/8/34 | | MTT assay | Decrease (50 %) | Approved | 31941776 |
| DrugRepV_7941 | Mycophenolic acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Influenza virus | A/New Caledonia/20/1999 | | MTT assay | Decrease (50 %) | Approved | 31941776 |
| DrugRepV_8146 | Fludarabine | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Vaccinia virus | NA | | NA | Decrease (99.1 %) | Approved | 32708182 |
| DrugRepV_8147 | Clofarabine | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8150 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved | 32708182 |
| DrugRepV_8153 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved | 32708182 |
| DrugRepV_8155 | Abitrexate | Antineoplastic and Immunomodulating Agents | Gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and acute lymphocytic leukemia | Vaccinia virus | NA | | NA | Decrease (62.2 %) | Approved | 32708182 |
| DrugRepV_8166 | Cladribine | Antineoplastic and Immunomodulating Agents | Lymphoproliferative diseases | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8183 | Ethinyl estradiol | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (53.3 %) | Approved | 32708182 |
| DrugRepV_8197 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Vaccinia virus | NA | | NA | Decrease (96.6 %) | Approved | 32708182 |
| DrugRepV_8227 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (74.2 %) | Approved | 32708182 |
| DrugRepV_8229 | Bosutinib | Antineoplastic and Immunomodulating Agents | Chronic myelogenous leukemia (CML) | Vaccinia virus | NA | | NA | Decrease (81.8 %) | Approved | 32708182 |
| DrugRepV_8251 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Vaccinia virus | NA | | NA | Decrease (97.9 %) | Approved | 32708182 |
| DrugRepV_8252 | Etoposide | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (60.1 %) | Approved | 32708182 |
| DrugRepV_8254 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Vaccinia virus | NA | | NA | Decrease (72.6 %) | Approved, Investigational | 32708182 |
| DrugRepV_8264 | Afatinib | Antineoplastic And Immunomodulating Agents | Metastatic non-small cell lung cancer | Vaccinia virus | NA | | NA | Decrease (95.2 %) | Approved | 32708182 |
| DrugRepV_8269 | Gefitinib | Antineoplastic and Immunomodulating Agents | Non-small cell lung cancer | Vaccinia virus | NA | | NA | Decrease (91.2 %) | Approved, Investigational | 32708182 |
| DrugRepV_8272 | Neratinib | Antineoplastic And Immunomodulating Agents | Breast cancer | Vaccinia virus | NA | | NA | Decrease (56.7 %) | Approved, Investigational | 32708182 |
| DrugRepV_8273 | Erlotinib Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (66.8 %) | Approved | 32708182 |
| DrugRepV_8279 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Chikungunya virus | 122508 | NA | NA | Decrease (50 %) | Approved | 32469886 |
| DrugRepV_8280 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Chikungunya virus | 122508 | NA | NA | Decrease (50 %) | Approved | 32469886 |
| DrugRepV_8281 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Chikungunya virus | 122508 | NA | NA | Decrease (50 %) | Approved | 32469886 |
| DrugRepV_8298 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Enterovirus | NA | | NA | Decrease (50 %) | Approved | 32424333 |
| DrugRepV_8316 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Human immunodeficiency virus | NA | | NA | Decrease (50 %) | Approved | 31866007 |